Abstract
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3474-3479 |
| Number of pages | 6 |
| Journal | Clinical Cancer Research |
| Volume | 6 |
| Issue number | 9 |
| State | Published - 2000 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cancer Research
- Oncology